Venom-Based Polypeptide
Our flagship product is a venom-based polypeptide, a groundbreaking solution designed to reduce thromboinflammation and enhance the effectiveness of nanovehicle-based therapies.
The polypeptide targets and inhibits a key protein in the complement system, thereby preventing the formation of the membrane attack complex (MAC), a group of proteins that can puncture the cell membranes of nanovehicles and cause them to be destroyed by the immune system. The polypeptide also reduces the production of pro-inflammatory cytokines, which are molecules that cause inflammation and tissue damage.
Our venom-based polypeptide offers several benefits:
Improved Efficacy: Enhances the effectiveness of nanovehicle-based therapies by reducing thromboinflammation.
Targeted Action: Specifically targets a key protein in the complement system, reducing the risk of side effects.
Innovation: Leverages the power of venom research to pioneer a new approach to thromboinflammation.
Explore investment opportunities
Evaluation of Nanoparticle's thromboinflammation
Our patient-specific evaluation service is designed to provide valuable insights into thromboinflammation and its impact on the introduction of nanovehicles into the bloodstream.
The service involves the analysis of various biomarkers, including complement activation, thrombin generation, platelet activation, and inflammation. The evaluation data is interpreted and reported using a proprietary algorithm that calculates a score for each biomarker and a composite score for the overall thromboinflammation status.
Our evaluation service offers several benefits:
Personalized Insights: Provides patient-specific evaluations, offering valuable insights tailored to each individual.
Informed Decision-Making: Helps researchers and pharmaceutical companies make informed decisions about nanovehicle-based therapies.
Risk Management: Aids in understanding and managing the risks associated with introducing nanovehicles into the bloodstream.
Individual Evaluation
$TBA
/ Nanovehicle
One evaluation
One parameter
Report document
Best for:
Occasional testing or initial trials.
Monthly Subscription
$TBA
/month
Up to 10 evaluations per month.
2 parameters
Report document
Best for: Regular monitoring
and ongoing research projects
Yearly Subscription
$TBA
/year
Up to 50 evaluations per month.
3 parameters
Report document
Best for: Long-term research studies
and development projects
Limited to Hospitals of the Algerian Northern Territory
C5-inhibitor Resistance Assessment
This service uses a novel test method that measures the residual activity of C5 in the presence of Eculizumab in aHUS patients.
The assessment results can inform treatment decisions, such as switching to a different drug, increasing the dose or frequency of Eculizumab, or adding the polypeptide or other complement inhibitors.
Benefits
Specialized Assessment: Provides a specialized assessment of Eculizumab resistance, offering valuable insights for aHUS patients.
Informed Treatment Decisions: Helps hospitals and healthcare professionals make informed treatment decisions.
Early Detection: Allows for the early detection of Eculizumab resistance, improving patient outcomes.
Starter
$720
DZD
1 evaluation for 1 patient
Sample Collection
C5 level assessement
Monthly Subscription
$3,000
/month
Up to 5 evaluations per month
Data Interpretation
Report document
Consultation and Support
Yearly Subscription
$35k
/year
Up to 52 evaluations
Data Interpretation
Report document
Consultation and Support
Take the next step with MIRAI
Copyright © Mirai Biotech 2023. All Rights Reserved.